tailieunhanh - Advanced breast cancer: This guideline updates and replaces NICE technology appraisal guidance 62 (capecitabine), 54 (vinorelbine) and 30 (taxanes)

Screening interventions should ideally be delivered through primary health care or as close to the community as possible. In countries where other vertical programmes for sexual and reproductive health, sexually transmitted infections (STI), oncology, and/or adolescent and youth services exist, cervical cancer prevention should be integrated into these services. Developing a new vertical programme specifically for cervical cancer prevention should be avoided. | NHS National Institute for Health and Clinical Excellence Issue date February 2009 Advanced breast cancer Diagnosis and treatment This guideline updates and replaces NICE technology appraisal guidance 62 capecitabine 54 vinorelbine J and 30 taXanes NICE clinical guideline 81 Developed by the National Collaborating Centre for Cancer NICE clinical guideline 81 Advanced breast cancer diagnosis and treatment Ordering information You can download the following documents from CG081 The NICE guideline this document - all the recommendations. A quick reference guide - a summary of the recommendations for healthcare professionals. Understanding NICE guidance - a summary for patients and carers. The full guideline - all the recommendations details of how they were developed and reviews of the evidence they were based on. For printed copies of the quick reference guide or Understanding NICE guidance phone NICE publications on 0845 003 7783 or email publications@ and quote N1794 quick reference guide N1795 Understanding NICE guidance . NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales. This guidance represents the view of NICE which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient in consultation with the patient and or guardian or carer and informed by the summary of product characteristics of any drugs they are considering. Implementation of this guidance is the responsibility of local commissioners and or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance in their local context in light .